Overview

Acute Lymphocytic or Lymphoblastic Leukemia (ALL) Therapeutics Market Introduction

Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics Market is estimated to value over USD 3.4 billion by 2027 end and register a CAGR of over 5% during the forecast period 2020 to 2027.

 Acute lymphocytic/lymphoblastic Leukaemia (ALL) is a type of cancer that is developed from immature lymphocytes. ALL usually develops in the bone marrow and it quickly invades other body parts like the spleen, lymph nodes, liver, central nervous system and the blood. There can be non-specific symptoms and may include feeling tired and weak, bruises, paler skin, nose bleeds, severe and frequent bleeding gums; shortness of breath, weight loss and loss of appetite. Different therapeutics are used for ALL treatment. 

 

Based on drug, the acute lymphocytic/lymphoblastic Leukaemia (ALL) market is divided into Hyper-CVAD Regimen, Linker Regimen, Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), and Oncaspar. 

urthermore, targeted drugs & immunotherapy are predicted to grow at the fastest growth rate during the forecast period as it is widely used in patients who do not respond to chemotherapy and these drugs have shown immense potential in the relapsed acute lymphocytic leukaemia treatment. Therefore, these factors contribute to the acute lymphocytic/lymphoblastic leukaemia (ALL) market growth.

 

North America occupied the largest acute lymphocytic/lymphoblastic Leukaemia (ALL) market share in 2018 and is projected to maintain its lead over the forecast period due to high cost of treatments, easy availability of treatments, and presence of a majority of key players. Nonetheless, the Asia-Pacific is expected to exhibit the highest growth rate during the forecast period, owing to a rise in patient awareness towards cancer care and high population base.

 

Key market players include Erytech Pharma, Spectrum Pharmaceuticals Inc., Genman A/S, Bristol-Myers Squibb Company, Genzyme Corp. (Sanofi), Pfizer Inc., Sigma-tau spa, Novartis AG, Celegene Corp., Juno Therapeutics Inc.

 

Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Segmentation:

By Product

  • Chemotherapy
    • Hyper-CVAD
    • CALGB 8811 Regimen
    • Linker Regimen
    • Nucleoside Metabolic Inhibitors
    • Oncaspar
  • Targeted Therapy
  • Radiation Therapy
  • Stem Cell Transplantation

 

By Type

  • Philadelphia Chromosome
    • Positive Ph (Ph+)
    • Negative Ph (Ph-)
  • Precursor B-Cell ALL
  • T-Cell ALL

 

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

FutureWise Key Takeaways:

• Growth prospects

• SWOT analysis 

• Key trends 

• Key data-points affecting market growth 

 

Objectives of the Study:

• To provide with an exhaustive analysis on the global acute lymphocytic/lymphoblastic Leukaemia (ALL) therapeutics market by product, by type and by region

• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)

• To evaluate and forecast micro-markets and the overall market 

• To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa

• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

• Profiling of companies to evaluate their market shares, strategies, financials and core competencies

$3450
Ask For Discount Buy Now

Need Assistance

--------

UK : +44 141 628 9353
US : +1 347 709 4931

OR

Contact Sales

What you get

  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included

  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics